Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) EPS (Basic): 2012-2024

Historic EPS (Basic) for Theravance Biopharma (TBPH) over the last 13 years, with Dec 2024 value amounting to -$1.15.

  • Theravance Biopharma's EPS (Basic) rose 126.92% to $0.07 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.58, marking a year-over-year increase of 157.43%. This contributed to the annual value of -$1.15 for FY2024, which is 15.00% down from last year.
  • Per Theravance Biopharma's latest filing, its EPS (Basic) stood at -$1.15 for FY2024, which was down 15.00% from -$1 recorded in FY2023.
  • Over the past 5 years, Theravance Biopharma's EPS (Basic) peaked at $11.85 during FY2022, and registered a low of -$4.73 during FY2020.
  • In the last 3 years, Theravance Biopharma's EPS (Basic) had a median value of -$1 in 2023 and averaged $3.23.
  • Per our database at Business Quant, Theravance Biopharma's EPS (Basic) skyrocketed by 410.21% in 2022 and then tumbled by 108.44% in 2023.
  • Theravance Biopharma's EPS (Basic) (Yearly) stood at -$4.73 in 2020, then rose by 19.24% to -$3.82 in 2021, then soared by 410.21% to $11.85 in 2022, then plummeted by 108.44% to -$1 in 2023, then fell by 15.00% to -$1.15 in 2024.